Phase I trial of 90Y-ibritumomab tiuxetan i patients with relapsed B-cell non-Hodgkin's lymphoma following high-dose chemotherapy and autologous stem cell transplantation

Research output: Contribution to journalArticle

25 Scopus citations

Fingerprint Dive into the research topics of 'Phase I trial of <sup>90</sup>Y-ibritumomab tiuxetan i patients with relapsed B-cell non-Hodgkin's lymphoma following high-dose chemotherapy and autologous stem cell transplantation'. Together they form a unique fingerprint.

Medicine & Life Sciences